Anthem Biosciences has opened its much-anticipated Initial Public Offering (IPO) today, aiming to raise ₹3,395 crore through the book-building route.
The entire issue is an Offer for Sale (OFS), meaning existing shareholders are offloading 5.96 crore equity shares. No fresh capital will be infused into the company, and the proceeds will go directly to the selling shareholders.
What Does the IPO Structure Mean?
Since the IPO is purely an OFS, investors should note that the company won’t receive any funds from this public issue. Instead, it’s a way for current stakeholders to partially or fully exit their holdings.
This structure is common among mature companies looking to give early investors or promoters an exit route, rather than raise fresh funds for expansion.
“The IPO is not about funding growth but about providing liquidity to current shareholders,” say market experts.
Also Read: Travel Food Services Makes Modest Stock Market Debut with 2.38% Premium
GMP Shows Positive Sentiment
As of Day 1, the grey market premium (GMP) for Anthem Biosciences indicates strong demand among informal traders, often seen as an early indicator of listing performance.
While GMP trends are not official, they offer a glimpse into investor sentiment before allotment and listing. A healthy GMP generally hints at potential listing gains — but investors are advised to look beyond the buzz and study fundamentals.
Should You Subscribe?
The decision to invest in any IPO should factor in:
The company’s business model and profitability
Strength of the pharma and biosciences sector
Market conditions and valuation
Long-term growth potential
Since Anthem Biosciences is a known name in the biopharma space, and GMP trends are positive, many investors may find this IPO appealing. However, because this is an OFS, it’s important to analyze the financials and company fundamentals rather than be swayed by hype.
Note: Always consult your financial advisor before applying.
Check This:
